Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2013-03-12 | Peter S. Ringrose, Ph.D. has served as a director of Theravance since April 2010. ... Dr. Ringrose's significant scientific leadership experience in the pharmaceutical industry contributed to our conclusion that Dr. Ringrose should serve as a director. |
| 2014-04-15 | Peter S. Ringrose, Ph.D., has served as a director of Theravance since April 2010. Dr. Ringrose was Chief Scientific Officer and President of Bristol Myers Squibb Pharmaceutical Research Institute from 1997-2002 and Senior Vice-President for Worldwide Drug Discovery at Pfizer Inc from 1982-1996. ... His significant scientific leadership experience in the pharmaceutical industry contributed to our conclusion that Dr. Ringrose should serve as a director. |
| Filing Date | Source Excerpt |
|---|---|
| 2006-04-25 | Peter S. Ringrose, Ph.D., age 60, joined us as a director in February 2005. Dr. Ringrose's experience in the pharmaceutical industry spans more than 30 years and includes key leadership positions as Senior Vice President for Worldwide Drug Discovery and Medicinal R & D Europe at Pfizer Inc, a pharmaceutical company, and Division Director of Chemotherapy, Infectious Diseases and Molecular Sciences at the Sandoz Research Institute in Vienna, Austria. ... Dr. Ringrose received a B.S., an M.A. and a Ph.D. from the University of Cambridge. |
| 2007-03-26 | Peter S. Ringrose, Ph.D., age 61, joined us as a director in February 2005. Dr. Ringrose's experience in the pharmaceutical industry spans more than 30 years and includes key leadership positions as Senior Vice President for Worldwide Drug Discovery and Medicinal R & D Europe at Pfizer Inc, a pharmaceutical company, and Division Director of Chemotherapy, Infectious Diseases and Molecular Sciences at the Sandoz Research Institute in Vienna, Austria. ... The following table shows for the fiscal year ended December 31, 2006 certain information with respect to the compensation of all non-employee directors of the Company: DIRECTOR COMPENSATION FOR FISCAL 2006 ... Peter S. Ringrose Fees Earned or Paid in Cash ($) 19,000 Option Awards ($) 107,672 Total ($) 126,672 |
| 2008-04-08 | Peter S. Ringrose, Ph.D., age 62, joined us as a director in February 2005. ... The Nominating and Corporate Governance Committee comprises three directors: Drs. Moos, Sherwin and Ringrose. ... The following table shows for the fiscal year ended December 31, 2007 certain information with respect to the compensation of all non-employee directors of the Company: Peter S. Ringrose, Ph.D. $37,500 Fees Earned or Paid in Cash, $59,590 Option Awards, Total $97,090. |
| 2009-04-15 | Peter S. Ringrose, Ph.D., age 63, joined us as a director in February 2005. ... The following three directors are the members of the Audit Committee: Messrs. Goodwin and Renton and Dr. Sherwin, all of whom were on the Audit Committee for all of fiscal year 2008. ... The following three directors are the members of the Nominating and Corporate Governance Committee: Drs. Moos, Sherwin and Ringrose, all of whom were on the Nominating and Corporate Governance Committee for all of fiscal year 2008. ... For services provided in 2008, each non-employee director of Rigel received a yearly retainer of $30,000, ... In the fiscal year ended December 31, 2008, the total cash compensation earned by non-employee directors was $187,689. |
| 2010-04-12 | Peter S. Ringrose, Ph.D., age 64, joined us as a director in February 2005. The Nominating and Corporate Governance Committee concluded that Dr. Ringrose should continue to serve as a director of Rigel in part due to his extensive research experience at large pharmaceutical companies, enabling the Board to benefit from his insight when negotiating partnership deals with large pharmaceutical companies, a core element of our business model. Dr. Ringrose's experience in the pharmaceutical industry spans more than 30 years and includes key leadership positions as Senior Vice President for Worldwide Drug Discovery and Medicinal R & D Europe at Pfizer Inc., a pharmaceutical company, and Division Director of Chemotherapy, Infectious Diseases and Molecular Sciences at the Sandoz Research Institute in Vienna, Austria. In 2002, Dr. Ringrose retired from Bristol-Myers Squibb, a pharmaceutical company, where he served as Chief Scientific Officer from January 2000 to December 2002, as well as President of the Pharmaceutical Research Institute from January 1997 to December 2002. Dr. Ringrose has served as chair of the Biotechnology and Biological Sciences Research Council (UK) from 2003 until 2009, and was a member of the UK Government's Technology Strategy Board. He is a Council member of the Foundation for Science and Technology in the United Kingdom and also chairs the Corporate Partnership Board at Pembroke College, Cambridge where he is a lifetime Honorary Pitt Fellow. Dr. Ringrose is also a non-executive director of Astex Therapeutics and Biotica Technology Ltd. (Cambridge UK) and served on the Scientific Advisory Boards of Schering-Plough Research Institute, Cempra Pharmaceuticals, Inc. and Accenture Inc. Dr. Ringrose also served on the board of governors for the New York Academy of Sciences from 1999 to 2005. He has served on the boards of Cambridge Antibody Technology Ltd., ImClone Systems, Inc. and Pfizer, Ltd. and on the Scientific Advisory Board at Merlin Biosciences Ltd. Dr. Ringrose received a B.S., an M.A. and a Ph.D. from the University of Cambridge. DIRECTOR COMPENSATION FOR FISCAL YEAR 2009 The following table shows for the fiscal year ended December 31, 2009 certain information with respect to the compensation of all non-employee directors of the Company: Peter S. Ringrose, Ph.D. $41,000 Fees Earned or Paid in Cash Option Awards $59,159 Total $100,159 |
| 2011-04-04 | Peter S. Ringrose, Ph.D., age 65, joined us as a director in February 2005. The Board concluded that Dr. Ringrose continues to be a valuable member of the Board in part due to his extensive research experience at large pharmaceutical companies, enabling the Board to benefit from his insight when negotiating partnership deals with large pharmaceutical companies, a core element of our business model. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2010: Peter S. Ringrose, Ph.D. $43,500 Option Awards $75,390 Total $118,890 |
| 2012-04-12 | Peter S. Ringrose, Ph.D., age 66, joined us as a director in February 2005. ... The Board has four standing committees: ... Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee ... The following three directors are the members of the Nominating and Corporate Governance Committee: Drs. Moos, Ringrose and Sherwin. ... For services provided in 2011, each non-employee director of Rigel received a yearly retainer of $30,000, ... In the fiscal year ended December 31, 2011, the total cash compensation earned by non-employee directors was $375,750. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2011: ... Peter S. Ringrose, Ph.D. ... Total $146,299. |
| 2013-04-03 | Peter S. Ringrose, Ph.D., age 67, joined us as a director in February 2005. The Board concluded that Dr. Ringrose continues to be a valuable member of the Board in part due to his extensive research experience at large pharmaceutical companies, enabling the Board to benefit from his insight when negotiating partnership deals with large pharmaceutical companies, a core element of our business model. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2012: Bradford S. Goodwin 67,000 76,760 143,760 Gary A. Lyons 65,000 76,760 141,760 Walter H. Moos, Ph.D. 65,000 76,760 141,760 Hollings C. Renton 57,000 76,760 133,760 Peter S. Ringrose, Ph.D. 67,500 76,760 144,260 Stephen A. Sherwin, M.D. 72,000 76,760 148,760 |
| 2014-04-08 | Peter S. Ringrose, Ph.D., age 68, joined us as a director in February 2005. The Board concluded that Dr. Ringrose continues to be a valuable member of the Board in part due to his extensive research experience at large pharmaceutical companies, enabling the Board to benefit from his insight when negotiating partnership deals with large pharmaceutical companies, a core element of our business model. ... On May 15, 2013, pursuant to the Directors' Plan, we granted options to purchase 15,000 shares of common stock to Peter S. Ringrose, each at an exercise price of $4.87 per share. These options vest in 12 equal monthly installments beginning on the grant date. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2013: Peter S. Ringrose, Ph.D. Fees Earned or Paid in Cash ($) 70,000 Option Awards ($) 51,477 Total ($) 121,477 |
| 2015-03-30 | Peter S. Ringrose, Ph.D., age 69, joined us as a director in February 2005. ... Dr. Ringrose was appointed Chairperson of the Nominating and Corporate Governance Committee effective April 1, 2015. Dr. Ringrose also serves as the Scientific Advisor to the Board. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2014: ... Peter S. Ringrose, Ph.D. 70,000 70,326 140,326 ... |
| 2016-03-28 | Peter S. Ringrose, Ph.D., age 70, joined us as a director in February 2005. ... Dr. Ringrose was made Chair of the Nominating and Corporate Governance Committee in January 2015. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2015: ... Peter S. Ringrose, Ph.D. Fees Earned or Paid in Cash $72,500, Option Awards $158,400, Total $230,900. |
| 2017-03-29 | Peter S. Ringrose, Ph.D., age 71, joined us as a director in February 2005. ... Dr. Ringrose was selected to serve as a member of the Board ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2016: Peter S. Ringrose, Ph.D. Fees Earned or Paid in Cash $70,000, Option Awards $57,148, Total $127,148. |
| 2019-04-09 | Peter S. Ringrose, Ph.D. joined us as a director. ... The following three directors are the current members of the Audit Committee: Mr. Goodwin, Mr. Katkin and Mr. Lapointe. ... The following three directors are the members of the Corporate Governance, Health Care Compliance Oversight and Nominating Committee: Mr. Lapointe, Dr. Ringrose, and Dr. Kotzin. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2018: Peter S. Ringrose 76,250 fees earned in cash, 103,664 option awards, total 179,914. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22